Is monthly retreatment with intravitreal bevacizumab (Avastin) necessary in neovascular age-related macular degeneration? [electronic resource]
Producer: 20110617Description: 307-14 p. digitalISSN:- 1177-5483
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.